Ginkgo Bioworks Holdings (DNA) Capital Expenditures (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Capital Expenditures of -$94000.0 for Q1 2026, down 1980.0% on a QoQ basis from $5000.0 in Q4 2025, and down 101.23% year-over-year from $7.6 million in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Capital Expenditures (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Capital Expenditures history runs 7 years deep, the most recent figure standing at -$94000.0 for Q1 2026.
- Quarterly Capital Expenditures fell 101.23% year-over-year to -$94000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$51000.0 (down 100.08% YoY) and the FY2025 annual result came in at $7.7 million, down 87.74% from the prior year.
- Capital Expenditures was -$94000.0 for Q1 2026 at Ginkgo Bioworks Holdings, down from $5000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $62.3 million in Q4 2024 and bottomed at -$30.2 million in Q3 2023.
- A 5-year average of $9.6 million and a median of $6.7 million in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures sank 415.64% — and 2025, when it surged 1282.89%.
- Ginkgo Bioworks Holdings' Capital Expenditures stood at $42.3 million in 2022, then declined by 9.94% to $38.1 million in 2023, then surged by 63.77% to $62.3 million in 2024, then sank by 99.99% to $5000.0 in 2025, then sank by 1980.0% to -$94000.0 in 2026.
- Business Quant data shows DNA's Capital Expenditures at -$94000.0 in Q1 2026, $5000.0 in Q4 2025, and $7.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | -94,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -94,000.00 |
| Mar 31, 2026 | -94,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 7.54 Mn |
| Sep 30, 2025 | 7.54 Mn |
| Jun 30, 2025 | -7.50 Mn |
| Jun 30, 2025 | -7.50 Mn |
| Mar 31, 2025 | 7.62 Mn |
| Mar 31, 2025 | 7.62 Mn |
| Dec 31, 2024 | 62.35 Mn |
| Dec 31, 2024 | 62.35 Mn |
| Sep 30, 2024 | -637,000.00 |
| Sep 30, 2024 | -637,000.00 |
| Jun 30, 2024 | -5.88 Mn |
| Jun 30, 2024 | -5.88 Mn |
| Mar 31, 2024 | 6.71 Mn |
| Mar 31, 2024 | 6.71 Mn |
| Dec 31, 2023 | 38.07 Mn |
| Dec 31, 2023 | 38.07 Mn |